

ANAGENICS

25 February 2026

1H26 Result

Anagenics Limited (ASX: AN1)



Anagenics is developing a portfolio of innovative health, beauty, and wellness brands and solutions

PRIORI[®]

THALGO
LA BEAUTÉ MARINE

/skin
regimen/**Lx**

[comfort zone]
conscious skin science

u s p a .

évolis[®]

ALPHA+

MANDA


Anagenics is Successfully Restructured...

During FY25 Anagenics successfully completed a significant restructure, with the aim of improving profitability and ensuring sustainable earnings growth going forward:

- Rationalisation of the product portfolio was a key focus, in order to ensure Anagenics was bringing quality brands with clear customer propositions to market.
- Key growth developments included the signing of a multi-year exclusive agreement with Sydney-based York Street Brands for access to Anagenics' hair regrowth technology and products, targeting a minimum \$4.4m over 10 years and **currently runrating \$9m. This agreement delivered \$500k of royalties in 1H26.**
- Disposal of non-core business units such as the loss-making Face MediGroup has reduced Group overheads and complexity, contributing to **annualised cost savings of \$2.5m**. The Group also recently achieved an exit of 55 Clarence St via sublease, saving an additional ~\$100k in 2H26, and has resolved a majority of legacy creditor issues.

As a result of the above improvements, Anagenics has observed a significant improvement in operating cash flows and the Group is now expected to continue trading profitability through FY26. **Anagenics is today reporting a maiden profit for 1H26 of \$127k.**

Management and the board remain focused on further building on these gains in order to entrench long-term profitability for the benefit of our strategic partners and shareholders.



...and Positioned for Growth

In December 2025 Anagenics received firm commitments to raise A\$2.25m via an equity placement to institutional and sophisticated investors. This capital raising has since completed.

Funds raised will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, support working capital, and meet the costs of the placement.

Combined with the post-restructure shift to profitability, **Anagenics is now very well placed to execute against strategic priorities** in 2026 and beyond.

A key focus area is now further building out our quality brand relationships and actively pursuing **strategic initiatives where they are mutually beneficial to our partners and shareholders.**



1H26 Income Statement

Income Statement

A\$'000	1H25	1H26
Revenue	2,928	2,636
Cost of Sales	(1,346)	(1,140)
Gross Profit	1,582	1,496
Gross Profit margin	54.0%	56.8%
Other Income	392	-
Expenses	(2,438)	(1,369)
Net Profit Before Tax	(464)	127


Following the recent restructure, in 1H26 vs the pcp:

- 90% of Revenue has been retained;
- Gross Profit margin has improved by 280bps; and
- Operating Expenses have been reduced by 44%.

The overall result is a material turnaround in earnings, from a \$464k loss in 1H25 to a **maiden profit in 1H26 of \$127k**.

Operating Cash Flow Improvement

Operating Cash Flow (\$k)



Cash Flows continue to improve materially vs the pcp following last year's restructure.

The \$0.6m Operating Cash Outflow reported during 1H26 is a significant improvement from the \$1.2m Operating Cash Outflow reported in 1H25.

Resolution of outstanding creditors drove negative Operating Cash Flow during 1H26, and it is expected this impact will end in 2H26.

1H26 Balance Sheet

Balance Sheet

A\$'000	Jun-25	Dec-25
Cash and cash equivalents	396	294
Trade and other receivables	575	727
Inventories	968	993
Plant and equipment	17	18
Right of use assets	194	111
Intangibles	1,952	1,952
Total Assets	4,102	4,095
Trade and other payables	1,400	796
Loans and borrowings	541	856
Lease liabilities	221	131
Provisions	28	41
Lease liabilities	86	-
Total Liabilities	2,276	1,823
Total Equity	1,826	2,272

Over the past six months Anagenics has achieved a 20% reduction in liabilities, largely via a 43% improvement in creditor balances.

With minimal change in the company's asset base, this has **resulted in a 24% increase in Net Assets**.

Anagenics has also successfully completed a \$2.25m two-tranche equity raise, with the first tranche (\$0.3m) completing in December 2025 and the second tranche (\$1.9m) completing in February 2026 after receiving shareholder approval.

Funds received from the capital raising will be used to expand existing brands, pursue complementary value-accretive business opportunities, retire debt, working capital, and the costs of the placement.

Going Forward

With the business restructure now complete, the management and board of Anagenics are focused on:

Maintaining recent profitability

- Based on recent cost improvements and royalty wins

Reinforcing royalty revenue streams

- Targeting new agreements per the recent York Street Brands deal

New brand releases

- Continuously enhancing collection of brands such as Manda

Actively pursuing strategic initiatives

- To contribute revenue alongside the newly streamlined cost base, including targeted acquisitions where accretive to shareholders



A woman with dark hair pulled back, smiling, is shown from the chest up. She is holding a white, cylindrical bottle of skincare product in her right hand, tilted so that a single drop of clear liquid is falling from the opening. Her left hand is held palm up, ready to catch the drop. The background is a solid, dark brown color. The text "Key Brands" is overlaid in the center of the image in a white, serif font.

Key Brands

Key Brands – Beauty

Thalgo



French Marine Skincare brand founded in 1964 that specialises in products made with algae and marine extracts

Comfort Zone




Italian vegan & highly concentrated natural skincare with over 25 years in the spa and wellness sector

Priori



Pioneer in biotech-based skincare innovation; looks at skin's biological structure & metabolism and sources disruptive ingredients & molecules

Alpha-H




Pioneer of glycolic acid with an extensive line of exfoliating solutions

Skin Regimen LX



Formulated with high-tech, natural ingredients and a proprietary Longevity Complex™; scientifically proven to protect skin cell longevity, therefore, delaying cell ageing rate by 80%¹.

uspa.



Founded in 1995 in Melbourne on the belief self-care is an art form; crafting a spa range that went beyond the surface, offering the promise of a sensory journey.

1. Independent laboratory, in vitro test of the ingredient on fibroblasts, B-galactosidase quantification.

Key Brands – Hair

Manda



Products are formulated for daily rituals that promote strong, vibrant hair, especially for those with long hair or those aspiring to grow it longer. Each product is a step towards not just looking good, but feeling empowered and connected to a tradition of quality and care.

Evolis



Anti-ageing hair care collection focused on harnessing the latest scientific research to give thicker, stronger, healthier hair. Their scientists are hair biologists, who have developed patented formulas based on clinical studies with real results on real people.

Contact

Sandy Beard
Chair Anagenics Ltd.

Ph: 0412 308 263
E: sandy@xvgroup.com.au

